BioSpace News Archive

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of a case series in the journal Cardiovascular Revascularization Medicine describing successful uses of the Neovasc Reducer™ (“Reducer”) under a compassionate use protocol in the United States.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a PHASE 2A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF INTRAVENOUS ALLOGENEIC ADIPOSE-DERIVED MESENCHYMAL STROMAL CELLS TO TREAT POST COVID-19 “LONG HAUL” PULMONARY COMPROMISE (NCT04992247).

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today provided updates and anticipated milestones across its 2022 strategic objectives.

The Michael J. Fox Foundation for Parkinson’s Research announces a new training program to grow the global base of researchers studying the movement disorder dystonia.

Zynex, Inc. announced order growth and an increased Adjusted EBITDA estimate for Q4 2021.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders, and anti-viral indications, reported positive results of four preclinical dermal safety studies for Epoladerm™ (diclofenac epolamine).

UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met the primary and all ranked secondary endpoints.

Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, has initiated two self-selection studies for its erectile dysfunction (ED) drug STENDRA® (avanafil).

Nuclera, a UK-based biotech company developing cutting-edge benchtop protein printing technologies, announces the opening of its US subsidiary in Boston, MA.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, comments on an independent January 10 study, available here, that discovered that “Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants”.